• LAST PRICE
    1.5450
  • TODAY'S CHANGE (%)
    Trending Down-0.0150 (-0.9615%)
  • Bid / Lots
    1.5400/ 41
  • Ask / Lots
    1.5500/ 5
  • Open / Previous Close
    1.5100 / 1.5600
  • Day Range
    Low 1.4900
    High 1.5700
  • 52 Week Range
    Low 1.3200
    High 4.7200
  • Volume
    78,860
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 1.56
TimeVolumeGMDA
09:32 ET92751.5001
09:33 ET11001.495
09:37 ET2001.52
09:39 ET24001.52
09:42 ET41271.54
09:50 ET5001.5117
09:51 ET33801.52
10:00 ET14951.54
10:09 ET9001.5574
10:11 ET1001.545
10:13 ET23721.57
10:18 ET1001.56
10:20 ET26901.5527
10:22 ET26211.55
10:26 ET1191.5599
10:44 ET2211.55
10:45 ET55291.53
10:47 ET2001.53
10:49 ET1001.535
10:51 ET18561.5399
10:54 ET103511.52
10:56 ET8501.52
10:58 ET8161.52
11:00 ET9001.52
11:02 ET17001.5166
11:03 ET16051.52
11:05 ET31551.5285
11:07 ET39681.54
11:12 ET2101.535
11:14 ET9951.5397
11:18 ET4211.54
11:23 ET14001.5469
11:25 ET6001.54
11:27 ET3731.535
11:30 ET5461.535
11:32 ET5461.535
11:34 ET3601.53
11:36 ET16131.55
11:38 ET2001.545
11:39 ET2951.545
11:41 ET5771.545
11:43 ET1841.545
11:45 ET3001.54
11:48 ET1951.55
11:50 ET4821.55
11:54 ET5791.545
11:57 ET2841.545
11:59 ET1951.545
12:01 ET1821.545
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesGMDA
Gamida Cell Ltd
116.0M
-1.1x
---
United StatesOLMA
Olema Pharmaceuticals Inc
115.3M
-1.1x
---
United StatesTRVI
Trevi Therapeutics Inc
114.5M
-2.4x
---
United StatesATHA
Athira Pharma Inc
120.3M
-1.5x
---
United StatesNVCT
Nuvectis Pharma Inc
111.1M
0.0x
---
United StatesALZN
Alzamend Neuro Inc
110.8M
-8.2x
---
As of 2022-12-02

Company Information

Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The following are the Company's clinical pipeline products: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.

Contact Information

Headquarters
PO Box 34670JERUSALEM, Israel 91340
Phone
---
Fax
---

Executives

Non-Executive Independent Chairman of the Board
Robert Blum
President, Chief Executive Officer, Director
Abigail Jenkins
Chief Financial Officer
Shai Lankry
Chief Operating Officer, Chief Compliance Officer
Michele Korfin
Chief Scientific Officer
Tracey Lodie

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$116.0M
Revenue (TTM)
$0.00
Shares Outstanding
74.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.57
EPS
$-1.47
Book Value
$0.73
P/E Ratio
-1.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.